COVID-19 can trigger Hashimoto's thyroiditis. A prospective study (PMC 10031076) tracked patients after SARS-CoV-2 infection and found TPO antibody positivity doubled: 15.7% versus 7.7% in controls. Lui et al. reported 25% TPO antibody positivity at three-month follow-up. Onset ranges from 7 to 90 days after acute infection, with 80% of cases occurring in women and a mean age of 40. The mechanism involves three converging pathways: molecular mimicry between spike protein and thyroid peroxidase, direct viral invasion through ACE2 receptors on thyroid cells, and cytokine storm damage to thyroid tissue. This connection has implications for millions of people who recovered from COVID and now face unexplained fatigue, weight gain, or brain fog.
How SARS-CoV-2 Attacks the Thyroid: Three Pathways
The thyroid gland expresses ACE2 receptors at higher density than most organs. ACE2 is the entry point SARS-CoV-2 uses to infect cells. Thyrocytes (the cells that produce thyroid hormones T3 and T4) sit exposed to viral binding. Autopsy studies of COVID-19 patients have confirmed SARS-CoV-2 RNA inside thyroid tissue, establishing direct thyroid tropism.
This direct invasion damages thyrocytes through two mechanisms. First, viral replication destroys the host cell. Second, infected thyrocytes release intracellular thyroglobulin and thyroid peroxidase into surrounding tissue, where the immune system encounters these proteins as foreign antigens. The result is an inflammatory cascade targeting the thyroid.
Molecular Mimicry
Vojdani et al. (2021) mapped structural homology between SARS-CoV-2 spike protein and human tissue proteins. The spike protein shares 27 to 56% sequence similarity with thyroid peroxidase (TPO). Antibodies generated against the spike protein cross-react with TPO, triggering autoimmune thyroid destruction even after the virus is cleared.
This is the same mechanism implicated in other post-infectious autoimmune diseases. Streptococcal pharyngitis triggers rheumatic heart disease through molecular mimicry between streptococcal M protein and cardiac myosin. SARS-CoV-2 does something analogous with thyroid tissue. Arevalo-Cortes (2024) published a detailed review confirming that COVID-specific antibodies bind thyroid antigens in vitro.
Cytokine Storm and Thyroid Infiltration
Severe COVID-19 triggers an IL-6 and TNF-alpha surge that damages tissue indiscriminately. The thyroid is particularly vulnerable because of its high vascularity and thin capsule. IL-6 levels above 80 pg/mL (common in hospitalized COVID patients) correlate with subacute thyroiditis onset in prospective studies.
Even mild COVID infections produce measurable cytokine elevation. Patients who never required hospitalization still show IL-6, IL-1beta, and TNF-alpha increases sufficient to breach the thyroid's defenses. The assumption that only severe COVID triggers thyroid autoimmunity is incorrect. Mild infections carry risk too, albeit at lower rates.
How Common Is Post-COVID Hashimoto's?
The prospective study (PMC 10031076) provides the strongest prevalence data. Researchers followed COVID-19 survivors and matched controls over 12 months, testing thyroid antibodies at baseline, 3 months, 6 months, and 12 months. TPO antibody positivity reached 15.7% in the COVID group versus 7.7% in controls. That represents a doubling of risk.
Lui et al. found even higher rates in a Hong Kong cohort: 25% TPO antibody positivity at three months post-infection. A subset of these patients progressed to clinical hypothyroidism requiring levothyroxine within the first year.
Case series data paints a consistent picture across geographies. Mohammadi (2023) reviewed published cases and identified a pattern: female predominance (80%), mean age 40, onset between 7 and 90 days post-infection. Prior autoimmune history was absent in most cases, meaning SARS-CoV-2 triggered de novo thyroid autoimmunity in previously healthy individuals.
Vaccination data offers an indirect control. Some studies report thyroiditis following mRNA vaccination at lower rates than post-infection thyroiditis. The spike protein alone (delivered by vaccine) triggers fewer thyroid events than the full virus, suggesting that direct thyroid invasion and cytokine storm contribute independently beyond molecular mimicry.
Reinfection compounds the risk. Each COVID infection restimulates the molecular mimicry cascade. A patient who had mild TPO elevation after a first infection may develop clinical Hashimoto's after a second or third. Cumulative immune insult matters. This pattern mirrors post-streptococcal glomerulonephritis, where repeated exposures amplify the autoimmune response with each round.
Subacute Thyroiditis Versus New-Onset Hashimoto's
Post-COVID thyroid disease presents in two distinct forms, and the distinction determines your treatment timeline.
Subacute thyroiditis (de Quervain's thyroiditis) appears 2 to 8 weeks after infection. The thyroid becomes tender, sometimes visibly swollen. Patients experience a triphasic pattern: initial thyrotoxicosis (as damaged thyrocytes dump stored hormone), followed by hypothyroidism (as the gland depletes its hormone stores), followed by recovery. Most cases resolve within 3 to 6 months without permanent thyroid damage. Pain responds to NSAIDs or short-course corticosteroids. This is inflammatory thyroiditis, not autoimmune thyroiditis.
New-onset Hashimoto's thyroiditis follows a different trajectory. TPO and thyroglobulin antibodies appear and persist. The thyroid undergoes progressive lymphocytic infiltration. Unlike subacute thyroiditis, Hashimoto's does not self-resolve. Once the autoimmune process establishes itself, it requires long-term management. Post-COVID Hashimoto's behaves identically to conventional Hashimoto's in terms of progression, treatment, and monitoring needs.
The overlap between these two conditions creates diagnostic confusion. Both cause fatigue, hypothyroid symptoms, and abnormal TSH. Antibody testing at 3 months distinguishes them: subacute thyroiditis produces transient antibody elevation that normalizes; Hashimoto's produces persistent, often rising antibody titers.
Symptoms: When COVID Damages Your Thyroid
Post-COVID thyroid dysfunction shares symptoms with long COVID, making identification difficult without lab testing. Fatigue, brain fog, weight gain, cold intolerance, hair loss, and depression appear in both conditions. Patients and physicians frequently attribute these symptoms to long COVID alone, missing the treatable thyroid component.
Two symptoms point more specifically toward thyroid involvement. Neck tenderness or anterior neck swelling (goiter) suggests direct thyroid inflammation. Constipation combined with dry skin and brittle nails suggests hypothyroidism rather than general post-viral fatigue.
The diagnostic trap: a patient with "long COVID" symptoms who never gets thyroid labs drawn. Every patient with persistent fatigue, cognitive impairment, or unexplained weight gain beyond 8 weeks post-COVID should receive a full thyroid panel. The test costs under $100. The missed diagnosis costs months or years of unnecessary suffering.
A subset of patients presents with autoimmune disease symptoms beyond the thyroid. Post-COVID immune dysregulation can trigger multiple autoimmune processes simultaneously. Joint pain may signal early rheumatoid arthritis. Dry eyes and mouth may indicate Sjogren's syndrome. Skin changes may point toward psoriasis. If symptoms extend beyond classic hypothyroidism, a broader autoimmune workup (ANA, RF, anti-CCP, ESR, CRP) is warranted.
Which Labs to Request (and When)
A standard TSH alone is insufficient for post-COVID thyroid evaluation. Request the complete panel.
TSH (thyroid-stimulating hormone): the screening test. Elevated TSH suggests hypothyroidism. Suppressed TSH during the thyrotoxic phase of subacute thyroiditis can confuse the picture if tested too early.
Free T4 and Free T3: direct measurement of circulating thyroid hormones. Low Free T4 with elevated TSH confirms primary hypothyroidism. Low Free T3 with normal Free T4 suggests impaired T4-to-T3 conversion, common in inflammatory states.
TPO antibodies: the Hashimoto's marker. Persistent elevation above 34 IU/mL confirms autoimmune thyroiditis. Serial measurements track disease progression or, in favorable cases, antibody decline.
Thyroglobulin antibodies (TgAb): a second autoimmune marker. Some Hashimoto's patients are TPO-negative but TgAb-positive. Testing both catches cases that a single antibody test misses.
For functional versus standard thyroid lab ranges, conventional medicine considers TSH normal up to 4.5 mIU/L. Functional medicine targets 0.5 to 2.0 mIU/L for optimal thyroid function. The gap matters: a patient with TSH of 3.8 after COVID is "normal" by standard criteria but suboptimal by functional standards, and may already be symptomatic.
Monitoring Schedule: First Year Post-COVID
Baseline (immediately upon suspicion): Full panel (TSH, Free T4, Free T3, TPO antibodies, TgAb).
3 months post-infection: Repeat full panel. This is the critical decision point. If antibodies are declining and TSH normalizing, subacute thyroiditis is resolving. If antibodies are stable or rising, Hashimoto's is establishing itself.
6 months: Repeat TSH, Free T4, and TPO antibodies. Assess symptoms. If hypothyroidism persists, levothyroxine discussion is appropriate.
12 months: Full panel again. Patients with normal labs at 12 months can transition to annual monitoring. Patients with persistent antibodies or abnormal TSH require ongoing quarterly monitoring.
Is Post-COVID Hashimoto's Reversible?
Subacute thyroiditis: yes, in most cases. The triphasic pattern (thyrotoxicosis, hypothyroidism, recovery) completes within 3 to 6 months. Approximately 5 to 15% of subacute thyroiditis cases progress to permanent hypothyroidism.
New-onset Hashimoto's: the honest answer is that established Hashimoto's is a chronic condition. Complete reversal is uncommon. Meaningful improvement is achievable. TPO antibody titers can decrease substantially with targeted intervention (selenium, myo-inositol, vitamin D optimization, AIP diet). Some patients achieve antibody normalization within 12 to 24 months, particularly when caught early.
Early intervention matters more than for conventional Hashimoto's. Post-COVID Hashimoto's is new-onset by definition. The autoimmune process has not had years to destroy thyroid tissue. The window for reducing antibody burden and preserving thyroid function is wider than in a patient diagnosed after a decade of subclinical progression.
The analogy is fire damage. Subacute thyroiditis is a flash fire that burns through and leaves the structure intact. Hashimoto's is a slow-burning fire inside the walls. Catching it early, while the structure is still sound, determines whether the building can be saved or merely stabilized.
When to Start Levothyroxine
Levothyroxine is the standard treatment for hypothyroidism, including post-COVID Hashimoto's. The timing depends on symptom severity and lab values.
Start immediately if: TSH exceeds 10 mIU/L. Free T4 is below the reference range. Symptoms are significantly impairing quality of life.
Consider starting if: TSH is between 4.5 and 10 mIU/L with persistent symptoms. This is subclinical hypothyroidism. Guidelines vary: the American Thyroid Association recommends treatment when TSH exceeds 10, while many endocrinologists treat at lower thresholds in symptomatic patients, particularly those under 65.
Watch and retest if: TSH is mildly elevated (2.5 to 4.5) with positive antibodies but minimal symptoms. Subacute thyroiditis may still be resolving. Starting levothyroxine during the hypothyroid phase of subacute thyroiditis creates a dependency that was never needed. Retesting at 3 months avoids premature treatment.
Typical starting dose: 25 to 50 mcg daily, titrated every 6 to 8 weeks based on TSH response. The goal is symptom resolution with TSH in the 0.5 to 2.0 mIU/L range.
The Post-COVID Hashimoto's Protocol
This protocol combines standard Hashimoto's interventions with COVID-specific immune recovery support. Evidence grades reflect the quality of human clinical data. For a complete Hashimoto's supplement guide, see our dedicated article.
Foundation (Grade A to B Evidence)
Selenium 200 mcg daily (Grade A for Hashimoto's). The CATALYST trial (2019) and Huwiler meta-analysis (2024) confirm that selenium reduces TPO antibodies in Hashimoto's patients. Selenium is a cofactor for glutathione peroxidase and deiodinase enzymes, both critical for thyroid function and antioxidant defense. COVID-19 depletes selenium through oxidative stress. Post-COVID patients start from a lower baseline, making supplementation more urgent. Selenomethionine form absorbs best. Do not exceed 200 mcg daily; higher doses carry toxicity risk. For the full evidence review, see our selenium for Hashimoto's guide.
Vitamin D3 4,000 to 5,000 IU daily with K2 (Grade A). The VITAL trial (2022, BMJ) demonstrated 22% reduction in new autoimmune disease incidence with 2,000 IU daily. Post-COVID patients benefit from higher doses because SARS-CoV-2 infection depletes vitamin D through inflammatory catabolism, and vitamin D deficiency independently predicts worse COVID outcomes and prolonged recovery. Target serum 25(OH)D: 40 to 60 ng/mL. Pair with 100 to 200 mcg vitamin K2 (MK-7) to direct calcium into bone. Test levels before starting and every 3 months until stable.
Omega-3 (EPA + DHA) 2 to 3 g daily (Grade B). EPA and DHA generate specialized pro-resolving mediators (resolvins, protectins) that terminate inflammatory cascades. Post-COVID inflammation often persists for months as a low-grade smolder. Omega-3 fatty acids address this residual inflammation while also reducing cardiovascular risk, which is elevated post-COVID. Triglyceride-form fish oil absorbs better than ethyl ester formulations. Take with meals containing fat.
AIP elimination diet (Grade B). Abbott et al. (2019) demonstrated significant symptom reduction in Hashimoto's patients following the autoimmune protocol diet. The diet removes gluten, dairy, grains, legumes, nightshades, and processed sugars for 30 to 90 days, then systematically reintroduces foods. Post-COVID patients often report increased food sensitivities. The AIP diet reduces the antigenic burden on an already dysregulated immune system. Gluten is particularly relevant: gliadin shares structural similarity with thyroid tissue, creating an additional molecular mimicry pathway independent of SARS-CoV-2.
COVID-Specific Additions (Grade B to C)
NAC (N-acetylcysteine) 600 to 1,200 mg daily (Grade B). NAC replenishes glutathione, the body's primary intracellular antioxidant. COVID-19 depletes glutathione stores through sustained oxidative stress. Low glutathione impairs thyroid peroxidase function and reduces selenium's protective capacity. NAC also thins mucus (relevant for post-COVID respiratory symptoms) and modulates NF-kB inflammatory signaling. Split dosing (600 mg twice daily) maintains more consistent glutathione levels than a single dose.
Zinc 30 mg daily (Grade B). Zinc deficiency is documented in hospitalized COVID-19 patients and persists into convalescence. Zinc is required for T cell maturation and thyroid hormone receptor binding. Zinc picolinate or zinc bisglycinate absorb better than zinc oxide. Supplementation beyond 40 mg elemental zinc daily for extended periods can deplete copper; monitor if supplementing long-term.
Magnesium glycinate 300 to 400 mg daily (Grade B). Magnesium participates in over 300 enzymatic reactions including thyroid hormone synthesis. Deficiency is common post-COVID (documented in ICU cohorts and outpatient follow-up studies) and causes symptoms that overlap with hypothyroidism: fatigue, muscle cramps, insomnia, and brain fog. Glycinate form offers superior absorption and minimal GI distress compared to magnesium oxide. Evening dosing supports sleep quality, which is frequently disrupted post-COVID.
Myo-inositol 600 mg with selenium 83 mcg (Grade B). The combination of myo-inositol and selenium outperformed selenium alone in reducing TSH and TPO antibodies in the Nordio (2017) and Zuhair (2024) trials. Myo-inositol improves thyroid cell signaling through the TSH receptor pathway. For new-onset post-COVID Hashimoto's, this combination targets the autoimmune process at an earlier and potentially more modifiable stage. For details, see our myo-inositol for Hashimoto's guide.
Advanced Options (Grade B, Prescription or Specialist-Guided)
Low-dose naltrexone (LDN) 1.5 to 4.5 mg nightly (Grade B). LDN modulates immune function through transient opioid receptor blockade, upregulating endogenous endorphin production and shifting immune balance away from autoimmune overactivity. Multiple case series document TPO antibody reductions and symptom improvement in Hashimoto's patients on LDN. For post-COVID autoimmunity, LDN's immune-regulatory properties address both the thyroid autoimmune process and the broader immune dysregulation that characterizes long COVID. LDN requires a prescription and compounding pharmacy. Start at 1.5 mg and titrate up over 4 to 8 weeks. See our LDN for Hashimoto's guide and the broader LDN for autoimmune disease overview.
GI-MAP stool testing. Post-COVID gut dysbiosis is documented in multiple studies: reduced Faecalibacterium prausnitzii, increased opportunistic pathogens, and diminished microbial diversity persisting months after infection. Gut barrier dysfunction (elevated zonulin) drives systemic immune activation that can perpetuate thyroid autoimmunity. GI-MAP testing identifies specific pathogens, commensal imbalances, and inflammatory markers (calprotectin, secretory IgA) that guide targeted intervention. This is a functional medicine test, not standard care; discuss with a practitioner experienced in gut-immune assessment.
Already Had Hashimoto's Before COVID?
COVID-19 flares existing Hashimoto's disease. Patients with established diagnoses report worsening symptoms, rising antibody titers, and medication dose increases following infection.
The mechanism is compounding. A thyroid gland already under autoimmune attack faces additional molecular mimicry (new cross-reactive antibodies), cytokine surge damage (IL-6 and TNF-alpha further infiltrating already-compromised tissue), and oxidative stress depleting the selenium and glutathione reserves that buffer autoimmune damage.
Practical steps for existing Hashimoto's patients post-COVID: request thyroid labs (TSH, Free T4, TPO antibodies) within 4 to 6 weeks of infection. Expect your levothyroxine dose may need upward adjustment. Increase selenium to 200 mcg if not already supplementing. Add NAC 600 mg twice daily for glutathione repletion. Recheck labs at 3 months and adjust.
Do not assume worsening symptoms are "just long COVID." The thyroid component is treatable.
Patients on biologics or immunosuppressants for other autoimmune conditions face additional complexity. COVID-19 infection while immunosuppressed may produce a blunted but prolonged inflammatory response. The thyroid damage accumulates over a longer window. Coordinate with both your prescribing specialist and an endocrinologist when managing post-COVID thyroid flares alongside other autoimmune medications.
Post-COVID Hashimoto's Versus Long COVID: Separating the Overlap
The symptom lists are nearly identical. Fatigue, brain fog, exercise intolerance, hair loss, weight changes, depression, and joint pain appear in both long COVID and Hashimoto's. Without lab testing, differentiating them is impossible.
Both conditions can coexist. A patient may have genuine long COVID (autonomic dysfunction, persistent viral reservoirs, microclot pathology) alongside post-COVID Hashimoto's. Treating the thyroid component resolves the thyroid-driven symptoms while leaving any non-thyroid long COVID symptoms unmasked for separate evaluation.
The key differentiator: thyroid labs. If TSH is elevated, Free T4 is low, and TPO antibodies are positive, hypothyroidism is contributing to symptoms regardless of whether long COVID is also present. Starting levothyroxine and the supplement protocol above addresses the treatable fraction. If symptoms persist after thyroid optimization, the remaining symptoms warrant long COVID-specific evaluation.
This two-step approach prevents the common error of attributing all symptoms to one cause and either overtreating or undertreating the individual components.
Post-COVID Immune Reset Strategies
Beyond thyroid-specific interventions, the post-COVID immune system benefits from broader recovery support. For a comprehensive overview of post-COVID autoimmune protocols, see our dedicated guide.
Sleep optimization. Post-COVID sleep architecture is disrupted in 40 to 60% of patients. Poor sleep elevates IL-6 and cortisol, both of which worsen thyroid autoimmunity. Magnesium glycinate before bed, consistent sleep-wake timing, and complete darkness address the most common post-COVID sleep disturbances. Melatonin 0.5 to 3 mg can assist short-term resynchronization but should not replace sleep hygiene fundamentals.
Graduated exercise. Exercise intolerance is a hallmark of both long COVID and hypothyroidism. Resuming high-intensity exercise too early exacerbates both conditions. Start with walking (20 to 30 minutes daily), then progress to light resistance training over 4 to 8 weeks as thyroid function stabilizes. Monitor heart rate: post-COVID patients frequently exhibit disproportionate tachycardia during exercise that resolves over months. Resistance training supports thyroid function through improved insulin sensitivity and glucose disposal, both of which are impaired in hypothyroid states.
Stress reduction. Cortisol suppresses TSH secretion and impairs T4-to-T3 conversion. Post-COVID patients already carry elevated baseline cortisol from infection-related adrenal stress. Active stress management (breathwork, meditation, vagal tone exercises) reduces the cortisol load on thyroid function. This is not a soft recommendation. Cortisol directly inhibits thyroid hormone production and conversion through measurable enzymatic pathways.
Gut restoration. SARS-CoV-2 infects intestinal epithelial cells through the same ACE2 receptor pathway it uses to enter thyrocytes. Post-COVID gut dysbiosis (reduced microbial diversity, elevated zonulin, impaired tight junction integrity) drives systemic immune activation through the gut-thyroid axis. Fasano's research established that intestinal permeability precedes and perpetuates autoimmune disease. Addressing gut barrier function with L-glutamine (5 to 10 g daily), zinc carnosine, and bone broth supports the immune recalibration necessary for thyroid autoimmune recovery. A GI-MAP test identifies specific dysbiotic patterns that guide targeted probiotic and antimicrobial intervention.
Frequently Asked Questions
Can COVID-19 cause Hashimoto's disease?
Yes. Prospective data shows TPO antibody positivity doubles after COVID-19 infection (15.7% versus 7.7% in controls). Three mechanisms contribute: molecular mimicry between spike protein and TPO (Vojdani 2021 documented 27 to 56% structural homology), direct viral invasion through ACE2 receptors on thyrocytes, and cytokine-mediated thyroid damage during the inflammatory response. Onset typically occurs 7 to 90 days after acute infection.
How soon after COVID should I test my thyroid?
If you develop fatigue, weight gain, brain fog, cold intolerance, or neck tenderness within 3 months of COVID-19 infection, request a full thyroid panel immediately. For asymptomatic individuals, baseline testing at 3 months post-infection is reasonable. The complete panel should include TSH, Free T4, Free T3, TPO antibodies, and thyroglobulin antibodies. A single TSH test is insufficient to detect early autoimmune thyroiditis.
Is post-COVID thyroiditis permanent?
It depends on the type. Subacute thyroiditis (de Quervain's) typically resolves within 3 to 6 months, with 85 to 95% of patients recovering full thyroid function. New-onset Hashimoto's thyroiditis is chronic but manageable. Early intervention with selenium, vitamin D, and dietary modification can reduce antibody titers and slow progression. Some early-stage patients achieve antibody normalization, particularly when treatment begins within the first year of onset.
What supplements help post-COVID Hashimoto's?
The strongest evidence supports selenium 200 mcg daily (Grade A: reduces TPO antibodies in multiple trials), vitamin D3 4,000 to 5,000 IU daily (Grade A: VITAL trial showed 22% autoimmune risk reduction), and omega-3 fatty acids 2 to 3 g daily (Grade B: anti-inflammatory). COVID-specific additions include NAC 600 to 1,200 mg daily for glutathione repletion, zinc 30 mg daily for immune support, and magnesium 300 to 400 mg daily. The myo-inositol plus selenium combination shows particular promise for new-onset cases.
Can COVID vaccines trigger Hashimoto's?
Thyroiditis following mRNA COVID vaccination has been reported in case reports at rates substantially lower than post-infection thyroiditis. The mechanism (spike protein molecular mimicry with TPO) is shared, but the magnitude of immune activation is smaller without direct viral thyroid invasion and cytokine storm. Most post-vaccination thyroiditis cases are subacute and self-resolving. The risk-benefit calculation overwhelmingly favors vaccination: COVID infection triggers thyroid autoimmunity at higher rates than vaccination does.
Should I see an endocrinologist or my primary care doctor?
Start with your primary care physician for initial thyroid labs. If TPO antibodies are positive and TSH is abnormal, referral to an endocrinologist is appropriate. Patients with coexisting long COVID symptoms may also benefit from a long COVID clinic that can coordinate thyroid evaluation alongside autonomic, cardiac, and neurological assessment. For advanced options like LDN, a functional medicine practitioner experienced in autoimmune conditions can provide compounding pharmacy guidance.
How long does post-COVID thyroid dysfunction last?
Subacute thyroiditis resolves in 3 to 6 months for the majority. New-onset Hashimoto's requires indefinite monitoring. Most patients stabilize within 12 to 18 months with appropriate treatment (levothyroxine if needed plus the supplement protocol described above). TPO antibody trends over the first year predict long-term trajectory: declining antibodies suggest favorable prognosis; stable or rising antibodies indicate chronic autoimmune thyroiditis requiring ongoing management. Annual thyroid panels are recommended indefinitely for anyone who developed TPO antibodies post-COVID.
Building Your Post-COVID Thyroid Recovery Plan
Start with labs. Request the full panel: TSH, Free T4, Free T3, TPO antibodies, thyroglobulin antibodies, and serum 25(OH)D. Without lab data, every intervention is guesswork.
Begin the foundation supplements (selenium, vitamin D, omega-3) while waiting for results. These carry minimal risk and address documented post-COVID deficiencies. Add NAC and magnesium for glutathione repletion and enzymatic support.
If labs confirm Hashimoto's (persistent TPO antibodies with TSH elevation), implement the full Hashimoto's natural treatment protocol. Discuss levothyroxine timing with your physician. Consider myo-inositol plus selenium for early-stage disease. Explore LDN with a knowledgeable prescriber if standard approaches provide incomplete relief.
Retest at 3, 6, and 12 months. Track your antibody trend. Adjust your protocol based on objective lab data, not symptoms alone.
Take the free 3-minute AutoimmuneFinder quiz to build a personalized, evidence-graded protocol matched to your specific condition, severity, and current medications.
This article is for educational purposes only and does not constitute medical advice. Hashimoto's thyroiditis and post-COVID conditions require professional medical supervision. Do not start, stop, or change any supplement or medication without consulting your endocrinologist or primary care physician. All dosage recommendations should be discussed with your healthcare provider before implementation.